CALC · CalciMedica, Inc.
$0.46
-0.01 (-1.19%)
At close · Aug 28
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plans, we believe our cash and cash equivalents will be sufficient to fund our current operations into the second half of 2027. As a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$15.86M
Shares
34.14M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$29.56M
-115.8%
FY2025
Diluted EPS
-$9.85
-61.5%
FY2025
Operating Cash Flow
-$21.18M
-0.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $451K | $713K | $1.01M | — | — | — | — | — | |
| $12.55M | $15.23M | $14.48M | $15.86M | $8.35M | $18.9M | $20.96M | $30.58M | |
| $7.08M | $7.89M | $9.73M | $22.22M | $5.84M | $17.04M | $8.87M | $6.92M | |
| — | — | — | $58K | $52K | — | — | — | |
| — | — | — | — | $3M | — | — | — | |
| $19.63M | $23.12M | $24.2M | $38.08M | $14.19M | $35.95M | $29.83M | $37.5M | |
| -$19.63M | -$23.12M | -$24.2M | -$38.08M | -$14.19M | -$35.95M | -$29.83M | -$37.5M | |
| $1.3M | $1.42M | $0 | — | — | — | — | — | |
| — | — | — | — | $575K | $126K | $143K | $393K | |
| -$1.61M | -$6.44M | $10.5M | $3.72M | $6.37M | — | — | — | |
| — | -$29.56M | -$13.7M | — | — | — | — | — | |
| $0 | $0 | $0 | $1000 | $1000 | — | — | — | |
| -$21.24M | -$29.56M | -$13.7M | -$34.36M | -$7.82M | -$35.82M | -$27.53M | -$37.04M | |
| -$21.24M | -$29.56M | -$13.7M | -$34.36M | -$9.14M | -$35.82M | -$34.72M | -$44.09M | |
| -$21.24M | -$29.57M | -$13.7M | -$34.36M | -$9.14M | -$35.83M | -$27.54M | -$37.03M | |
| USD/shares | -$6.75 | -$9.85 | -$6.10 | -$38.30 | -$555.80 | -$8.45 | — | — |
| USD/shares | -$6.80 | -$9.85 | -$6.10 | -$38.30 | -$555.80 | -$8.45 | — | — |
| shares | — | 3M | 2.25M | 897.25K | 16.45K | 4.24M | 1.32M | 263.98K |
| shares | — | 3M | 2.25M | 897.25K | 16.45K | 4.24M | 1.32M | 263.98K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.77×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.89×
Peer medians compare against the 219 similar-size Biotechnology companies (of 508 listed).
Key facts
CIK
1534133
CUSIP
38942Q202
13F (30d)
35 filings
33 filers
Visit website
Investor relations